Infigratinib API is a pharmaceutical-grade Fibroblast Growth Factor Receptor (FGFR1, FGFR2, and FGFR3) tyrosine kinase inhibitor developed for the treatment of FGFR2 fusion or rearrangement-positive cholangiocarcinoma and other cancers driven by FGFR genetic alterations.
Infigratinib selectively inhibits abnormal FGFR signaling pathways responsible for uncontrolled tumor growth, angiogenesis, and cancer cell survival. By blocking these pathways, it suppresses tumor proliferation and supports precision medicine approaches in oncology. It is primarily formulated into oral capsule formulations for targeted cancer therapy.
Manufactured under WHO-GMP-certified facilities, our Infigratinib API is produced using advanced pharmaceutical manufacturing technologies to ensure exceptional purity, stability, and batch-to-batch consistency. Every batch undergoes rigorous quality testing and is supplied with complete documentation, including Certificate of Analysis (CoA), Material Safety Data Sheet (MSDS), Technical Data Sheet (TDS), and Product Specifications.
Infigratinib API is used in oral targeted oncology formulations for treating FGFR2 fusion or rearrangement-positive cholangiocarcinoma and other cancers with FGFR alterations.
Infigratinib selectively inhibits FGFR1, FGFR2, and FGFR3 tyrosine kinases, blocking signaling pathways that promote cancer cell growth, survival, and angiogenesis.
Yes. We provide CoA, MSDS, Technical Data Sheet (TDS), Product Specifications, and complete regulatory documentation with every shipment.
Yes. We supply Infigratinib API in commercial quantities with worldwide export support and customized packaging.
Get Bulk Quote via WhatsApp